

The data presented in the following reports reflect the NNTC central database as of  
February 03, 2025

## Usage Statement

*Distribution of the data contained in this report through publication or presentation should be reported to the Data Coordinating Center. Reporting usage of the NNTC resources helps to ensure continuation of this valuable resource!*

The NNTC is directly funded by the NIMH, NIA, NIDA, and NINDS.

Questions regarding these data should be directed to the Data Coordinating Center  
The Emmes Company  
Rockville, MD  
nntc@emmes.com

## **Suppressed Cohort Overview: PWH**

Cohort Enrollment & Study Status

CNS Specimens Available

Peripheral Specimens Available

Fluids Available (%)

Demographics

cART Era Demographics

HIV Characteristics

cART Era Viral Load

Pathological Conditions: Year of Autopsy

Last Psychiatric Diagnosis

Baseline Psychiatric Diagnosis

Cognitive Diagnosis (%)


Change in Cognitive Diagnosis

Neurologic Diagnoses

Concomitant Medications

Ancillary Lab Measurements

# Suppression Cohort Overview



**Total number of suppressed active cases is 66. The total number of suppressed autopsy cases is 80. The total number of suppressed inactive cases is 27.**

Criteria 1: Participants have been followed for at least 5 years. There must be at least 1 undetectable viral load within last 1 year, or 2 undetectable viral loads within last 2. Over last 5 year period, there must be at least 4 undetectable viral loads. Note that “blips” of detectable virus are allowed, however these must be <1000 copies/mL during this 5 year period.

Criteria 2: Participants have been followed for at least 2 years. There must be at least 1 undetectable viral load within last 6 months. Note that “blips” of detectable virus are allowed, however these must be <1000 copies/mL during this 2 year period.

Longitudinal Cohort: Participants enrolled with 2 or more study visits.

Tissue Bank: Participants deceased with autopsy.

51 cases meet both criteria. 29 autopsy cases met both criteria.

Inactive cases are either lost to follow-up/administratively censored/withdrawn (N=2) or deceased without autopsy (N=25).

\* 0 autopsy cases included in Cross Sectional Cohort; 38 autopsy cases included in Longitudinal Cohort.

^ 0 autopsy cases included in Cross Sectional Cohort; 71 autopsy cases included in Longitudinal Cohort.

## CNS Specimens Available


Type:	PWH
Frozen Brain	75
Fixed Brain	72
Spinal Cord	72
Cerebellum	62
Brain Stem	61
Frontal Lobe	60
Parietal Lobe	59
Occipital Lobe	59
Temporal Lobe	59
Thalamus	56
Basal Ganglia	54
Dorsal Root Ganglia	51
Hippocampus	50
Trigeminal Ganglia	24
Occipital Pole	5

\*Several of the smaller brain categories listed were approved by the Steering Committee on 27JUN2017 to be reported centrally, and thus are currently underreported in the central inventory as sites work towards retrospectively updating specimen records. It is expected that the central inventory, including availability of these specimens, will continue to be updated prospectively.

## Peripheral Organ Specimens Available

Type:	PWH
Heart	73
Liver	72
Spleen	69
Kidney	66
Lung	66
Peripheral Nerve	62
Adipose Tissue	55
Bone Marrow	54
Muscle	54
Lymph Node	51
Bowel	39
Pituitary Gland	30
Testes	28
Hair	4

## Available Fluids



\*All-combinations (e.g., one specimen might be available ante-mortem while the other two might be ante- and post-mortem or any of the other 23 combinations where all 3 specimen availabilities are not the same).

Please note the totals listed above reflect only those cases who have a fixed brain specimen available and fluids collected within 1 year of death. Percentage labels not shown are 2% or less.

## Demographics\*

<u>N</u>	<u>73</u>
<u>Age</u>	
Mean	60.8
SD	8.9
25th Percentile	55
Median	60
75th Percentile	66

\*Cases with a fixed brain specimen available with a measurement at baseline and within 1 year of death.



## Demographics cont.\*

	<u>N</u>	<u>%</u>
<u>Sex</u>		
Male	55	75
Female	18	25
<u>Ethnicity</u>		
Hispanic origin	21	29
<u>Race</u>		
White	36	49
Black	29	40
Other	8	11


\*Cases with a fixed brain specimen available.

## Demographics cont.\*

	<u>N</u>	<u>%</u>
<u>Furthest Education</u>		
8th grade or less	4	6
Some High School	18	25
High School Gradudate	17	24
Some College/Associate's Degree	21	29
College Graduate	5	7
Advanced Degree work	7	10


\*Cases with a fixed brain specimen available.

## cART Era Demographics - Sex



\*The NNTC did not collect data before 1998.

## cART Era Demographics - Race



\*The NNTC did not collect data before 1998.

## HIV Characteristics of autopsy cases\*

	<u>N</u>	<u>%</u>
<u>Baseline HIV risk</u>		
IV drug use	24	33
Male to male sex	33	45
Heterosexual sex	16	22
<u>On ART</u>		
at baseline	71	97
at last visit	66	90

\*Cases with a fixed brain specimen available.

## *HIV Characteristics at time of death\**

### CD4 Count (N=66)

25th Percentile	197
Median	369
75th Percentile	572


### Log Plasma Viral Load\*\* (N=67)

25th Percentile	1.30
Median	1.70
75th Percentile	1.70

\*Cases with a fixed brain specimen available with a measurement at baseline and within 1 year of death.

\*\*Among those with known ARV medication status. 3 participants had detectable VL values of 0 where a viral log could not otherwise be calculated.

## cART Era Viral Load




\*Among those who have died during the cART era.

## Pathological Conditions: Year of Autopsy

Type:	Year of Autopsy		
	< 2010	2010-present	Total Cases
<i>Total Fixed Specimens</i>	18	54	72
Normal/minor neuropath changes	5 (28)	7 (13)	12 (17)
Other non-infectious pathology	6 (33)	28 (53)	34 (47)
Alzheimer's type 2 gliosis	1 (6)	8 (15)	9 (13)
Focal infarct	7 (39)	18 (34)	25 (35)
Hypoxic/ischemic damage	4 (22)	15 (28)	19 (26)
Aseptic Leptomeningitis	2 (11)	9 (17)	11 (15)
Microglial nodule encephalitis	0	1 (2)	1 (1)
Hemorrhage-parenchymal	0	6 (11)	6 (8)
Progressive Multifocal Leukoencephalopathy	0	1 (2)	1 (1)
Other infections	0	3 (6)	3 (4)




## Last Psychiatric Diagnosis



63% are Normal/Test Not Administered

\*Please note the totals listed above reflect only those cases who have a fixed brain specimen available and data from the PRISM/CIDI evaluation before death.


## Baseline Psychiatric Diagnosis



15% are Normal/Test Not Administered

\*Please note the totals listed above reflect only those cases who have a fixed brain specimen available and data from the PRISM/CIDI evaluation closest to baseline.


## Cognitive Diagnosis



ANI = Asymptomatic Neurocognitive Impairment  
 MCMD = Minor Cognitive Motor Disorder  
 MND = Minor Neurocognitive Disorder  
 HAD = HIV-Associated Dementia  
 NPI-O = Neuropsychological Impairment - Other cause, not HIV

\*Please note the totals listed above reflect only those cases who have a fixed brain specimen available.

## Change in Cognitive Diagnosis



## Neurologic Diagnoses\*

	<u>Last Dx</u>		<u>Baseline</u>	
	<u>N</u>	<u>%</u>	<u>N</u>	<u>%</u>
<b><u>Clinical Myelopathy</u></b>	<u>(N=49)</u>		<u>(N=71)</u>	
HIV associated	4	8	5	7
Other	0	0	2	3
None	45	92	64	90
<b><u>Neuropathy</u></b>	<u>(N=43)</u>		<u>(N=60)</u>	
HIV associated DSP	30	70	28	47
HIV/nucleoside	4	9	4	7
None	9	21	28	47

\*Cases with a fixed brain specimen available.

## Participants Reporting Concomitant Medications

Medication	# of Pts (N=71)	%
Central Nervous System Agents	68	95.8
Cardiovascular Drugs	63	88.7
Gastrointestinal Drugs	63	88.7
Vitamins	60	84.5
Anti-infective Agents	57	80.3
Hormones and Synthetic Substitutes	49	69
Electrolytic, Caloric, and Water Balance	47	66.2
Autonomic Drugs	46	64.8
Skin and Mucous Membrane Agents	38	53.5
Blood Formation, Coagulation, and Thrombosis Agents	35	49.3
Miscellaneous Therapeutic Agents	29	40.8
Eye, Ear, Nose, and Throat (EENT) Preparations	27	38
Antihistamine Drugs	26	36.6
Respiratory Tract Agents	20	28.2
Antineoplastic Agents	18	25.4
Pharmaceutical Aids	8	11.3
Local Anesthetics	7	9.9
Serums, Toxoids, and Vaccines	6	8.5
No medication use reported on at least one occasion	5	7
Smooth Muscle Relaxants	5	7

## Ancillary Lab Measurements

Ancillary Lab	Total # records overall	% cohort with at least 1 measure	Total # cases with baseline measure	% cohort with baseline & one other measure
<u>Miscellaneous Hematology</u>				
Red blood cells	196	13	3	4
Mean Corpuscular Hemoglobin (MCH)	195	13	3	4
Mean Corpuscular Volume (MCV)	1198	69	44	61
Mean Corpuscular Hemoglobin Concentration (MCHC)	188	11	3	4
Blood Red cell Distribution Width (RDW)	194	13	3	4
Blood Rapid Plasma Reagin (RPR)	107	44	16	17
Blood Neutrophil Percent	1149	68	44	61
Blood Lymphocyte Percent	1169	68	44	61
Blood Monocyte Percent	1156	68	44	61
Blood Eosinophil Percent	1153	68	44	61
Blood Basophil Percent	1151	68	44	61
Blood Mean Platelet Volume (MPV)	151	8	3	4
Blood CD3 Percent	11	3	1	0
Blood CD3 Absolute	11	3	1	0
<u>Miscellaneous Serology &amp; viral loads</u>				
Blood Hepatitis B Surface Antigens	115	61	34	28
Blood Hepatitis B Surface Antibodies	112	60	30	26
Blood Hepatitis B Core Antibodies	112	63	31	24
Blood Hepatitis B Viral Load	20	11	3	3
Blood Hepatitis C Antibodies (HCV)	134	60	35	31
Blood Hepatitis C Viral Load	76	36	11	13
<u>Miscellaneous Serology &amp; viral loads</u>				
COVID-19 Test Results (qualitative)	23	11	0	0

## Ancillary Lab Measurements cont.

Ancillary Lab	Total # records overall	% cohort with at least 1 measure	Total # cases with baseline measure	% cohort with baseline & one other measure
<u>Miscellaneous Blood Chemistries</u>				
Glucose	1121	68	44	61
Hemoglobin A1c	189	47	9	13
Sodium	1077	74	44	61
Calcium	1026	67	42	58
Chloride	1052	74	42	58
Potassium	1062	74	42	58
Total Protein	892	72	39	54
Alkaline Phosphatase	893	68	40	56
AST	877	68	38	53
ALT	892	68	40	56
Total Bilirubin	940	75	44	61
Direct Bilirubin	57	7	1	1
Creatinine	1078	72	44	61
BUN	1071	72	42	58
CO2	1046	68	42	58
PT	562	64	41	57
INR	563	64	41	57
Urate	10	6	1	0
Triglycerides	296	57	16	21
Cholesterol	298	57	15	19
LDL	280	56	15	19
HDL	286	58	17	21
Phosphorus	85	10	2	1
LDH	15	6	1	0



## Ancillary Lab Measurements cont.

Ancillary Lab	Total # records overall	% cohort with at least 1 measure	Total # cases with baseline measure	% cohort with baseline & one other measure
<u>Miscellaneous CSF values</u>				
CSF-VDRL Test	28	4	1	1
<u>Miscellaneous Urine values</u>				
Urinalysis: Glucose	461	63	40	53
Urinalysis: Protein	464	63	39	51
Urinalysis: pH	461	63	40	53
Urinalysis: Specific Gravity	458	63	40	53
Urinalysis: Ketones	458	61	39	51
Urinalysis: Bilirubin	458	63	40	53
Urine Toxicology; Methamphetamine	77	13	6	8
Urinalysis: Red Blood Cells	258	53	23	29
Urinalysis: White Blood Cells	254	53	23	29